. In the management recommendations for adult patients with LCH cladribine monotherapy is recommended in front line treatment of systemic therapy of single-system LCH with special site lesions, multifocal lesions and for multi-system LCH with or without involvement of high risk organs . Cladribine is alsoAuthor: Marlies E.H.M. van Hoef. The dosing of cladribine for all patients was based on one of the two intravenous regimens ( mg/kg for days every 28 days or 5 mg/m 2 for days every 28 days). The median follow-up for the entire cohort was years (95% CI) and the treatment outcomes are shown in Table virginxx.xyz by: 1.
mg/kg/day IV on days 1, 2, and 3 repeated every 28 days for up to 6 cycles in combination with cyclophosphamide has been evaluated in 2 randomized, phase 3 trials.  In 1 study, cladribine was administered over 30 minutes and the cyclophosphamide dosage was mg/m2/day IV over 30 to 60 minutes on days 1, 2, and 3; therapy. Thus, cladribine has major activity in adult LCH and warrants further investigation in both pediatric and adult LCH as a single agent and in combination with other drugs. View Show abstract.
Jun 15, · Only one patient had a documented infection, dermatomal herpes zoster. At a median follow-up of 42 months (range, 5 to 76), 12 patients remain alive and one patient has died. Thus, cladribine has major activity in adult LCH and warrants further investigation in both pediatric and adult LCH as a single agent and in combination with other drugs.